Lobe Sciences to Present Low-Dose L-130 Clinical Data at Summit

Lobe Sciences, a clinical-stage biopharmaceutical company, is set to present groundbreaking clinical data on its low-dose L-130 at the 9th Neuropsychiatric Drug Development Summit in Boston, Massachusetts, from September 15 to 17. Dr. Frederick D.

The presentation will focus on the Phase 1a first-in-human results of Conjugated Psilocin™ (L-130), highlighting its oral bioavailability, dose consistency, and the absence of hallucinogenic effects at low doses. Lobe Sciences aims to demonstrate that L-130 can be administered in a daily outpatient setting, potentially revolutionizing the way psychedelic therapeutics are used in clinical practice.

According to the press release, Lobe Sciences will also exhibit at the summit alongside senior leaders from major pharmaceutical companies, showcasing its commitment to advancing innovative therapies for neurological and rare diseases. The summit, which brings together key figures from the neuropsychiatric drug development community, provides a platform for Lobe Sciences to share its latest findings and engage with industry experts.

Dr. Sancilio’s presentation is scheduled for 11:00 a.m. ET on Wednesday, September 16, in the summit’s preclinical and translational track. The company’s lead CNS asset, L-130, is a patented new chemical entity initially being developed for cluster headache, with co-development programs underway for PTSD, substance use disorder, generalized anxiety disorder, and other neuropsychiatric disorders. Unlike conventional psilocybin, which produces highly variable psilocin exposure between patients, L-130 is designed to deliver psilocin directly with a predictable pharmacokinetic profile.

The presentation will argue that the therapeutic benefits of psilocin may be achieved at controlled exposure levels below those typically associated with hallucinations. This approach could potentially separate efficacy from the psychedelic experience, significantly expanding the clinical and commercial potential of psychedelic-derived medicines. Lobe Sciences is also advancing S-100, a novel therapeutic for sickle cell disease, with Phase 3 clinical development anticipated to commence in mid-2027.

The summit, which is expected to attract senior discovery, translational, clinical, regulatory, and business development leaders from large pharmaceutical companies, biotechnology companies, and investors, will provide a valuable opportunity for Lobe Sciences to network and discuss potential partnerships and collaborations.

Lobe Sciences’ participation in the summit underscores its ongoing commitment to advancing innovative therapies for neurological and rare diseases. The company’s presentation is anticipated to generate significant interest and discussion among attendees, potentially opening new avenues for the development and commercialization of its drug candidates.